Parkinson's Progression Markers Initiative - Parkinson's Disease Cohort (PPMI - PD)
PPMI-PD is designed to identify clinical, imaging, genetic and biospecimen markers of Parkinson's disease (PD) progression. At baseline, participants were at least 30 years old, had a clinical diagnosis of Parkinson's Disease (PD), and had a positive dopamine transporter single photon emission tomography (SPECT) result. They were recruited within 7 years of diagnosis. Over 700 participants were recruited for the study. Among the participants, over 400 were not being treated for PD despite having received a diagnosis, and almost 300 had rare genetic variants.
Study design
Cohort - clinical
Number of participants at first data collection
717 (participants)
Age at first data collection
≥ 30 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2010
Primary Institutions
Institute for Neurodegenerative Disorders (INDD)
University of California, San Francisco (UCSF)
Profile paper DOI
Not available
Funders
Michael J. Fox Foundation for Parkinson's Research
Ongoing?
Yes
Data types collected
- Computer, paper or task testing (e.g. cognitive testing, theory of mind doll task, attention computer tasks)
- Interview – face-to-face
- Interview – phone
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- None
- Diffusion Tensor Imaging (DTI)
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Single-photon emission computed tomography (SPECT)
- None
Engagement
Keywords
